Insights On Upstream Manufacturing

  1. Turning Gene Therapies Into Patient Reality: Large Scale Cost-Effective AAV Production 5/19/2026

    Understanding how upstream control, downstream efficiency, and process robustness scale together is essential for protecting supply and expanding patient access.

  2. The Science Fueling Cell Culture Optimization For Biologic Therapies 5/18/2026

    Boost mAb titers by over 60% with an optimized intensified fed-batch process, no new equipment required. See the data.

  3. In Vivo Manufacturing: When The Body Becomes The Bioreactor 5/15/2026

    Breakthrough therapies are reshaping medicine, but manufacturing complexity is holding them back. Discover how rethinking production and delivery could expand reach and improve patient experience.

  4. The Body As A Bioreactor – The Vision 5/15/2026

    As cell therapy manufacturing reaches its limits, a new model is emerging. Learn how in vivo approaches that harness the body as a bioreactor could expand access and reshape the future.

  5. Enabling A Four-Fold Increase In Titer For mAb Manufacturing 5/14/2026

    A platform-based upstream strategy increased monoclonal antibody titers fourfold, improving yield, efficiency, and scalability via optimized clones, process design, and rapid scale-up.

  6. Unlock The Potential Of GPEx® Lightning: Accelerate Your HEK Cell Line Development 5/8/2026

    Cut HEK cell line development to four months with 30% higher titers. GPEx® Lightning delivers faster, scalable biologics manufacturing. Access the full summary now.

  7. Comprehensive Bioprocess Control: Substrate, Metabolite And Product Analysis 5/6/2026

    Explore how multi-parameter bioprocess analyzers support monitoring of 30+ bioprocess parameters across mammalian and microbial systems to optimize yield and product quality.

  8. Rapid Selection Of High-Performance CHO Basal And Feed Media 5/5/2026

    A CHO-S bispecific antibody program needed a better basal and feed media combination. Learn how the screening of 180 conditions in 12 weeks identified one that delivered 38% higher titers.

  9. Advancing Cell Culture Strategies To Accelerate Biologics Development 5/5/2026

    Integrated stable expression strategies accelerate biologics material generation, improving scalability, consistency, and early developability insights while reducing bottlenecks, variability, and risks in transitioning from discovery to manufacturing.

  10. Aligning Upstream And Downstream Development (Part 2) 5/5/2026

    In Part 2 of this conversation on “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their discussion about how upstream and downstream development teams can work together to accelerate timelines and reduce risk and bottlenecks in process development.